Petrelintide
Also known as: Petrelintide
Petrelintide is a long-acting amylin analog in phase 2/3 development for weight management, notable for producing meaningful weight loss with markedly less gastrointestinal burden than incretin-based drugs.
Last updated
Mechanism of Action
Petrelintide is a long-acting analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells. It acts at amylin and calcitonin receptor complexes in the hindbrain to promote satiation (the sense of having finished a meal), slow gastric emptying, and suppress post-prandial glucagon secretion. This is a distinct pathway from GLP-1 receptor agonism, which is why the tolerability profile differs so sharply. The molecule was engineered for chemical and physical stability without fibrillation near neutral pH, which permits co-formulation and co-administration with other peptides — a deliberate design choice supporting future combination products.
- Half-life
- Approximately 10 days after subcutaneous injection in phase 1 trials, supporting once-weekly dosing.
- Administration Routes
- subcutaneous
- Research Status
- Clinical
Reported Benefits
- Up to 10.7% mean body weight reduction at week 42 in phase 2 (vs 1.7% placebo)
- No cases of vomiting reported at the maximally effective dose in phase 2
- No discontinuations for gastrointestinal adverse events at the maximally effective dose
- Once-weekly subcutaneous dosing
- Engineered for co-formulation with other peptides
- Studied as monotherapy rather than only as an add-on
Potential Side Effects
- Nausea (reported, but at markedly lower rates than incretin agonists)
- Injection-site reactions
- Long-term safety not yet established — phase 3 has not reported
- Full adverse-event profile at scale still unknown
Common Dosing
No established human dosing outside clinical trials. The phase 2 ZUPREME-1 trial evaluated once-weekly subcutaneous dosing over 42 weeks. Petrelintide is an investigational drug and is not approved for human use anywhere. Not medical or dosing advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Not approved for human use in any jurisdiction
- Pregnancy and breastfeeding
- No characterized interaction profile outside trial settings
No documented stacking partners for Petrelintide yet.